Breakfast breakthrough: skipping doses may be possible for kidney cancer drug
Knowledge-focused
Completed
This study tested whether taking the kidney cancer drug cabozantinib with a light breakfast changes how much drug gets into the body. Twelve patients with advanced kidney cancer took the drug both with and without breakfast to compare drug levels. The goal is to find a dosing sch…
Phase: PHASE2 • Sponsor: dr. Tom van der Hulle • Aim: Knowledge-focused
Last updated May 11, 2026 20:54 UTC